Rheumatoid arthritis disease activity assessed by patient-reported outcomes and flow cytometry before and after an additional dose of COVID-19 vaccine.
作者信息
Tedeschi Sara K, Stratton Jacklyn, Ellrodt Jack Elias, Whelan Mary Grace, Hayashi Keigo, Yoshida Kazuki, Chen Lin, Adejoorin Ifeoluwakiisi, Marks Kathryne Elizabeth, Jonsson A Helena, Rao Deepak A, Solomon Daniel H
机构信息
Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA
Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
出版信息
Ann Rheum Dis. 2022 Jul;81(7):1045-1048. doi: 10.1136/annrheumdis-2022-222232. Epub 2022 Feb 15.
Abstract
摘要
相似文献
1
Rheumatoid arthritis disease activity assessed by patient-reported outcomes and flow cytometry before and after an additional dose of COVID-19 vaccine.在额外一剂新冠疫苗接种前后，通过患者报告结局和流式细胞术评估类风湿性关节炎疾病活动度。
Ann Rheum Dis. 2022 Jul;81(7):1045-1048. doi: 10.1136/annrheumdis-2022-222232. Epub 2022 Feb 15.
2
Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.类风湿关节炎患者接种SARS-CoV-2 mRNA疫苗6个月后B细胞和T细胞免疫反应的动力学
Front Immunol. 2022 Feb 28;13:846753. doi: 10.3389/fimmu.2022.846753. eCollection 2022.
3
Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab.接受利妥昔单抗治疗的类风湿关节炎患者接种新型冠状病毒疫苗后特异性T细胞反应的存在情况。
Immunol Res. 2021 Aug;69(4):309-311. doi: 10.1007/s12026-021-09212-5. Epub 2021 Jul 29.
4
The T-cell response to SARS-CoV- 2 vaccination persists beyond six months in rheumatoid arthritis patients treated with rituximab.在用利妥昔单抗治疗的类风湿性关节炎患者中，T细胞对SARS-CoV-2疫苗接种的反应持续超过六个月。
Arthritis Res Ther. 2025 Apr 16;27(1):86. doi: 10.1186/s13075-025-03553-4.
5
Analysis of T-cell and Humoral Immune Response to SARS-CoV-2 Antigens in Rituximab-Treated Patients with Rheumatoid Arthritis Vaccinated with Combined Vector Vaccine Gam-COVID-Vac.分析利妥昔单抗治疗的类风湿关节炎患者接种联合载体疫苗 Gam-COVID-Vac 后对 SARS-CoV-2 抗原的细胞和体液免疫反应。
Bull Exp Biol Med. 2024 Apr;176(6):786-790. doi: 10.1007/s10517-024-06109-9. Epub 2024 Jun 19.
6
Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses.SARS-CoV-2 疫苗在接受 DMARDs 治疗的类风湿关节炎（RA）患者中的有效性：通过抗体和 T 细胞应答来确定。
RMD Open. 2022 Mar;8(1). doi: 10.1136/rmdopen-2021-002050.
7
8
Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis.甲氨蝶呤和糖皮质激素会削弱单剂量BNT162b2 mRNA新冠疫苗在慢性炎症性关节炎患者中的免疫原性，但抗细胞因子疗法不会。
Ann Rheum Dis. 2021 Dec;80(12):1635-1638. doi: 10.1136/annrheumdis-2021-220862. Epub 2021 Jun 25.
9
Impact of SARS-CoV-2 mRNA vaccine on arthritis condition in rheumatoid arthritis.新型冠状病毒 2 型 mRNA 疫苗对类风湿关节炎关节炎病情的影响。
Front Immunol. 2023 Aug 25;14:1256655. doi: 10.3389/fimmu.2023.1256655. eCollection 2023.
10
Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response.一名类风湿性关节炎患者接种BNT162b2加强针成功，且最初抗体反应呈阴性。
Ann Rheum Dis. 2021 Oct;80(10):1361-1362. doi: 10.1136/annrheumdis-2021-220834. Epub 2021 Jun 24.
引用本文的文献
1
Analysis of related factors for RA flares after SARS-CoV-2 infection: a retrospective study from patient survey.分析 SARS-CoV-2 感染后 RA 发作的相关因素：一项来自患者调查的回顾性研究。
Sci Rep. 2024 Feb 20;14(1):4243. doi: 10.1038/s41598-024-52748-3.
2
The Third Dose of BNT162b2 COVID-19 Vaccine Does Not "Boost" Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis.BNT162b2新冠疫苗第三剂不会“引发”类风湿性关节炎患者的病情复发和不良事件。
Biomedicines. 2023 Feb 23;11(3):687. doi: 10.3390/biomedicines11030687.
3
Is vaccination against COVID-19 associated with autoimmune rheumatic disease flare? A self-controlled case series analysis.接种 COVID-19 疫苗是否与自身免疫性风湿病发作有关？一项自身对照病例系列分析。
Rheumatology (Oxford). 2023 Apr 3;62(4):1445-1450. doi: 10.1093/rheumatology/keac484.
4
The Flare of Rheumatic Disease After SARS-CoV-2 Vaccination: A Review.接种 SARS-CoV-2 疫苗后风湿性疾病的 flares：综述。
Front Immunol. 2022 Jul 4;13:919979. doi: 10.3389/fimmu.2022.919979. eCollection 2022.
本文引用的文献
1
Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis.病理上扩增的外周辅助性T细胞亚群驱动类风湿关节炎中的B细胞。
Nature. 2017 Feb 1;542(7639):110-114. doi: 10.1038/nature20810.
2
Circulating plasmablasts/plasmacells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis.循环中的浆母细胞/浆细胞是类风湿关节炎患者抗瓜氨酸化蛋白抗体的来源。
Ann Rheum Dis. 2013 Jul;72(7):1259-63. doi: 10.1136/annrheumdis-2012-202893. Epub 2013 Apr 26.
3
Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c⁺ B-cell population is important for the development of autoimmunity.Toll 样受体 7（TLR7）驱动的新型 CD11c⁺B 细胞群体的积累对于自身免疫的发展很重要。
Blood. 2011 Aug 4;118(5):1305-15. doi: 10.1182/blood-2011-01-331462. Epub 2011 May 4.
4
Patient-centered rheumatoid arthritis disease activity assessment by a modified RADAI.采用改良的类风湿关节炎疾病活动指数进行以患者为中心的类风湿关节炎疾病活动评估。
J Rheumatol. 2008 Jul;35(7):1294-9. Epub 2008 May 15.
Zotero 插件